Skip To Main Content
Ravi Parikh on Muck Rack

Ravi Parikh

Verified
Atlanta
As seen in: Journal of Clinical Oncology, Medscape, HuffPost, Nature, The Washington Post, Washington Post Opinions, Wiley Online Library, Gizmodo, PLOS, PLOS ONE, The Atlantic, BMJ Open and
Oncologist @EmoryUniversity @WinshipatEmory; Director @HACLab_; Consultant Editor @JCO_ASCO; Columnist @Medscape; Board @CTACorg
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ravi

Contact Ravi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

When Patients Share Everything With an AI Chatbot : Risks and Opportunities of Large Language Models

|
By Ifeoma Ajunwa, Ravi Parikh Verified, I. Glenn Cohen
| JAMA: Journal of the American Medical Association Verified
In January 2026, OpenAI launched ChatGPT Health, a product that allows patients to sync their electronic health records (EHRs) and wellness app data directly with a large language model (LLM) and receive personalized responses to health queries. Microsoft Copilot has introduced a similar functionality for its LLM and others are entering the market.
Open in Who Shared Issue with article?

The arrival of digital twins and in silico trials in drug development

|
By Ashley L. Eadie, Holly Lynch, Naomi Scheinerman, Ravi Parikh Verified
| Nature Verified
The regulatory landscape for drug evaluation is shifting. For digital twins and in silico trials to become reliable evidence for drug approvals, these digital tools will require input from regulators and the public sector to ensure safe and responsible adoption.
Open in Who Shared Issue with article?

Advancing FDA New Approach Methodologies from animal models through digital twins

|
By Ashley L. Eadie, Holly Lynch, Naomi Scheinerman, Ravi Parikh Verified
| Nature Verified
Abstract In April 2025, the U.S. Food and Drug Administration announced immediate steps toward replacing animal testing for drug evaluation with New Approach Methodologies (NAMs)—modern laboratory techniques mimicking human tissues. However, significant gaps exist between current regulatory frameworks and these technologies’ promise.
Open in Who Shared Issue with article?
See all 287 licensed articles (319 Total)